Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TeLuRide-008: EIK1001 with pembrolizumab and chemotherapy in stage IV non-small cell lung cancer
PACTR202610584818528Phase 3Not yet recruiting
- Sponsor
- Eikon Therapeutics
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing EIK1001 + pembrolizumab + chemotherapy with Placebo + pembrolizumab + chemotherapy (2 arms). Planned start Jan 2026; status: not yet recruiting.
02
Drugs
BDB001
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on PACTR202610584818528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202610584818528.